Literature DB >> 2663422

Evolving concepts and issues in remyelination.

S K Ludwin1.   

Abstract

The ability of the central nervous system to undergo remyelination is now well established in both clinical and experimental situations. The focus of investigation has shifted from simple morphologic documentation to a detailed examination of the basic biologic processes controlling or limiting remyelination. Successful remyelination depends on an adequate number of oligodendrocytes, which may be provided either by proliferation of endogenous cells or by delivery of exogenous oligodendrocytes, which have been shown to be capable of remyelinating axons. It has recently been found that these transplanted cells are capable of significant migration to reach axons. The adhesion of myelinating cells to the demyelinated axon is probably another step in the process of remyelination and may require a form of cell adhesion molecule, although it is possible that the actual process of myelin wrapping depends on some other additional signal. Attempts to enhance remyelination will involve modulation of both the demyelinating event and these basic biological oligodendrocyte-axon interactions.

Entities:  

Mesh:

Year:  1989        PMID: 2663422     DOI: 10.1159/000111895

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  3 in total

1.  Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes.

Authors:  L Y Oh; P H Larsen; C A Krekoski; D R Edwards; F Donovan; Z Werb; V W Yong
Journal:  J Neurosci       Date:  1999-10-01       Impact factor: 6.167

2.  Oligodendrocytes from optic nerves subjected to long term Wallerian degeneration retain the capacity to myelinate.

Authors:  S K Ludwin
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Expression of carbonic anhydrase II mRNA and protein in oligodendrocytes during toxic demyelination in the young adult mouse.

Authors:  F A Tansey; H Zhang; W Cammer
Journal:  Neurochem Res       Date:  1996-04       Impact factor: 3.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.